Overview

Rifaximin SSD in Dementia Trial

Status:
RECRUITING
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
Using a new formulation of rifaximin, a non-absorbable antibiotic, to test if it can affect microbes in the gut of patients with dementia favorably.
Phase:
PHASE1
Details
Lead Sponsor:
Jasmohan Bajaj
Collaborator:
Bausch Health Americas, Inc.